Quadrant Capital Group’s Shockwave Medical, Inc. Common Stock SWAV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-536
Closed -$175K 2788
2024
Q1
$175K Buy
536
+69
+15% +$16.9K 0.01% 705
2023
Q4
$89K Sell
467
-230
-33% -$43.5K 0.01% 1069
2023
Q3
$139K Buy
697
+247
+55% +$58.4K 0.01% 697
2023
Q2
$128K Buy
450
+163
+57% +$45.3K 0.01% 723
2023
Q1
$62.2K Sell
287
-95
-25% -$18.5K 0.01% 1106
2022
Q4
$78.5K Sell
382
-166
-30% -$42K 0.01% 915
2022
Q3
$152K Buy
548
+344
+169% +$87.5K 0.02% 525
2022
Q2
$39K Buy
204
+32
+19% +$5.65K 0.01% 990
2022
Q1
$36K Buy
172
+5
+3% +$824 ﹤0.01% 1067
2021
Q4
$30K Sell
167
-6
-3% -$1.18K ﹤0.01% 1117
2021
Q3
$36K Buy
173
+6
+4% +$1.18K 0.01% 993
2021
Q2
$32K Buy
167
+2
+1% +$327 ﹤0.01% 1018
2021
Q1
$21K Buy
165
+4
+2% +$480 ﹤0.01% 1166
2020
Q4
$17K Hold
161
﹤0.01% 1176
2020
Q3
$12K Hold
161
﹤0.01% 1168
2020
Q2
$8K Buy
+161
New +$6.63K ﹤0.01% 1458

Other funds holding SWAV

Quadrant Capital Group's SWAV Position: Q2 2024 in Review

Quadrant Capital Group sold out of Shockwave Medical, Inc. Common Stock (SWAV) in Q2 2024, closing a stake of 536 shares — an estimated $175K sold.

Quadrant Capital Group first reported a position in SWAV in Q2 2020 and held it in 16 quarters. The position peaked at $175K in Q1 2024. 7 funds tracked by Wall St. Rank hold SWAV as of Q2 2024.

  • Quadrant Capital Group reported no remaining Shockwave Medical, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 536 Shockwave Medical, Inc. Common Stock shares in Q2 2024, an estimated $175K.
  • Quadrant Capital Group first reported a position in Shockwave Medical, Inc. Common Stock in Q2 2020 and held it in 16 quarters.
  • Quadrant Capital Group's Shockwave Medical, Inc. Common Stock position peaked at $175K in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Shockwave Medical, Inc. Common Stock as of Q2 2024.

Based on Quadrant Capital Group's 13F filing for Q2 2024, filed 12 Aug 2024.